Surrozen reloads with $50M for final dash to the clinic, shines some light on lead Wnt-modulating candidates

Amber Tong

Two rounds totalling $83 million have propelled Surrozen through preclinical proof-of-concept, culminating in two antibody candidates modulating the Wnt pathway for tissue regeneration. Now, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Surrozen reloads with $50M for final dash to the clinic, shines some light on lead Wnt-modulating candidates

Amber Tong

Sign up to read this article for free.

Senior AstraZeneca exec detained in China amid wider investigation

Pfizer to invest $1B in China over next five years — reports

Avid Bioservices to be sold to private equity firms for $1.1B

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Sur­rozen re­loads with $50M for fi­nal dash to the clin­ic, shines some light on lead Wnt-mod­u­lat­ing can­di­dates

Amber Tong

Sign up to read this article for free.

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Surrozen reloads with $50M for final dash to the clinic, shines some light on lead Wnt-modulating candidates

Senior AstraZeneca exec detained in China amid wider investigation

Pfizer to invest $1B in China over next five years — reports

Avid Bioservices to be sold to private equity firms for $1.1B

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks